Hi, I am Satohiro Masuda, My LiveDNA is 81.6080
 
   
  Home
 
 
 
Dr. Satohiro Masuda
 
Highest Degree: Ph.D. in Pharmaceutical Sciences from Kyoto University Hospital, Japan
 
Institute: Kyushu University Hospital, Japan
 
Area of Interest: Pharmacology and Toxicology
  •   Clinical Pharmacology
  •   Drug Transporter
  •   Nephrology
  •   Transplant Immunology
 
URL: http://livedna.org/81.6080
 
My SELECTED Publications
1:   Egawa, H., K. Taira, S. Teramukai, H. Haga and Y. Ueda et al., 2009. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: A single center experience. Dig. Dis. Sci., 54: 1347-1354.
CrossRef  |  
2:   Fukatsu, S., M. Fukudo, S. Masuda, I. Yano and T. Katsura et al., 2006. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab. Pharmacokinet, 21: 122-125.
CrossRef  |  
3:   Fukudo, M., I. Yano, A. Yoshimura, S. Masuda and M. Uesugi, et al., 2008. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics, 18: 413-423.
CrossRef  |  PubMed  |  
4:   Fukudo, M., I. Yano, S. Masuda, M. Goto and M. Uesugi et al., 2006. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther., 80: 331-345.
CrossRef  |  
5:   Fukudo, M., I. Yano, S. Masuda, M. Okuda and K.I. Inui, 2005. Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity. J. Pharmacol. Exp. Ther., 312: 816-825.
CrossRef  |  
6:   Fukudo, M., I. Yano, S. Masuda, S. Fukatsu and T. Katsura et al., 2005. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin. Pharmacol. Ther., 78: 168-181.
CrossRef  |  
7:   Fukudo, M., I. Yano, S. Masuda, T. Katsura and Y. Ogura et al., 2006. Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. Liver Trans., 12: 292-300.
CrossRef  |  
8:   Goto, M., S. Masuda, H. Saito and K.I. Inui, 2003. Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2. Biochem. Pharmacol., 66: 163-170.
CrossRef  |  
9:   Goto, M., S. Masuda, H. Saito, S. Uemoto, T. Kiuchi, K. Tanaka and K.I. Inui, 2002. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 12: 451-457.
PubMed  |  
10:   Goto, M., S. Masuda, T. Kiuchi, Y. Ogura and F. Oike et al., 2004. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 14: 471-478.
PubMed  |  
11:   Goto, M., S. Masuda, T. Kiuchi, Y. Ogura and F. Oike et al., 2008. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. J. Pharmacol. Exp. Ther., 325: 610-616.
CrossRef  |  Direct Link  |  
12:   Hashida, T., S. Masuda, S. Uemoto, H. Saito, K. Tanaka and K.I. Inui, 2001. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther., 69: 308-316. 2001. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther., 69: 308-316.
CrossRef  |  
13:   Ho, G., A. Yonezawa, S. Masuda, K.I. Inui and K.G. Sim et al., 2011. Maternal riboflavin deficiency, resulting in transient neonatal‐onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum. Mutat., 32: E1976-E1984.
CrossRef  |  
14:   Hodoshima, N., S. Masuda and K.I. Inui, 2007. Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal failure. Drug Metab. Pharmacokinet, 22: 419-427.
PubMed  |  
15:   Horiba, N., S. Masuda, A. Takeuchi, D. Takeuchi, M. Okuda and K.I. Inui, 2003. Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney. J. Biol. Chem., 278: 14669-14676.
CrossRef  |  
16:   Horiba, N., S. Masuda, A. Takeuchi, H. Saito, M. Okuda and K. Inui, 2004. Gene expression variance based on random sequencing in rat remnant kidney. Kidney Int., 66: 29-45.
CrossRef  |  
17:   Horiba, N., S. Masuda, C. Ohnishi, D. Takeuchi, M. Okuda and K.I. Inui, 2003. Na+-dependent fructose transport via rNaGLT1 in rat kidney. FEBS Lett., 546: 276-280.
CrossRef  |  
18:   Hosohata, K., S. Masuda, A. Yonezawa, M. Sugimoto and Y. Takada et al., 2009. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: A case-control study. Drug Metab. Pharmacokinet., 24: 458-463.
PubMed  |  Direct Link  |  
19:   Hosohata, K., S. Masuda, A. Yonezawa, T. Katsura and F. Oike et al., 2009. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res., 26: 1590-1595.
CrossRef  |  Direct Link  |  
20:   Hosohata, K., S. Masuda, T. Katsura, Y. Takada and T. Kaido et al., 2009. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Meta.b Dispos., 37: 821-826.
CrossRef  |  Direct Link  |  
21:   Hosohata, K., S. Masuda, Y. Ogura, F. Oike and Y. Takada et al., 2008. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab. Pharmacokinet., 23: 134-138.
Direct Link  |  
22:   Ichikawa, M., K. Miwa, T. Yamasaki, I. Nakagawa, S. Takizawa, S. Masuda and K.I. Inui, 2010. Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. J. Biochem., 148: 557-563.
CrossRef  |  
23:   Inui, K.I., S. Masuda and H. Saito, 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int., 58: 944-958.
CrossRef  |  Direct Link  |  
24:   Inui, K.I., T. Terada, S. Masuda and H. Saito, 2000. Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial Transplant, 15: 11-13.
CrossRef  |  
25:   Ito, T., I. Yano, S. Masuda, Y. Hashimoto and K. Inui, 1999. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharm. Res., 16: 534-539.
CrossRef  |  
26:   Ji, L., S. Masuda, H. Saito and K.I. Inui, 2002. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int., 62: 514-524.
CrossRef  |  
27:   Jiko, M., I. Yano, E. Sato, K. Takahashi and H. Motohashi et al., 2007. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol., 12: 284-290.
CrossRef  |  
28:   Kajiwara, M., S. Masuda, S. Watanabe, T. Terada, T. Katsura and K. Inui, 2012. Renal tubular secretion of varenicline by multidrug and toxin extrusion (MATE) transporters. Drug Metab. Pharmacokinet., 27: 563-569.
PubMed  |  Direct Link  |  
29:   Kamei, H., S. Masuda, T. Nakamura, F. Oike, Y. Takada and N. Hamajima, 2013. Association of transporter associated with antigen processing (TAP) gene polymorphisms in donors with acute cellular rejection in living donor liver transplantation. J. Gastrointestin. Liver. Dis., 22: 167-171.
PubMed  |  Direct Link  |  
30:   Kamei, H., S. Masuda, T. Nakamura, Y. Fujimoto and F. Oike, et al., 2013. Impact of glutathione S-transferase T1 gene polymorphisms on acute cellular rejection in living donor liver transplantation. Transpl. Immunol., 28: 14-17.
CrossRef  |  PubMed  |  Direct Link  |  
31:   Kimura, N., S. Masuda, T. Katsura and K.I. Inui, 2009. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem. Pharmacol., 77: 1429-1436.
CrossRef  |  
32:   Kimura, N., S. Masuda, Y. Tanihara, H. Ueo, M. Okuda, T. Katsura and K.I. Inui, 2005. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet, 20: 379-386.
CrossRef  |  
33:   Kodawara, T., I. Yano, S. Masuda, T. Ito and H. Wakasugi et al., 2001. Interaction of azole antifungal agents with human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. Xenobio Metabol. Dispos, 16: 5-11.
Direct Link  |  
34:   Kodawara, T., S. Masuda, H. Wakasugi, Y. Uwai and T. Futami et al., 2002. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res., 19: 738-743.
CrossRef  |  
35:   Masuda, S. and K.I. Inui, 2006. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther., 112: 184-198.
CrossRef  |  
36:   Masuda, S., 2003. Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metab. Pharmacokinet, 18: 91-103.
CrossRef  |  
37:   Masuda, S., A. Takeuchi, H. Saito, Y. Hashimoto and K.I. Inui, 1999. Functional analysis of rat renal organic anion transporter OAT-K1: Bidirectional methotrexate transport in apical membrane. FEBS Lett., 459: 128-132.
CrossRef  |  
38:   Masuda, S., A. Takeuchi, S. Saito, Y. Hashimoto and K.I. Inui, 2000. Tubular Localization and Drug Recognition of Organic Anion Transporters OAT-K1 and OAT-K2. In: Control and Diseases of Sodium Dependent Transport Proteins and Ion Channels, Suketa, Y. (Ed.). Elsevier, Amsterdam, pp: 335-336.
39:   Masuda, S., H. Saito and K. Inui, 1997. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. J. Pharmacol. Exp. Ther., 283: 1039-1042.
Direct Link  |  
40:   Masuda, S., H. Saito, H. Nonoguchi, K. Tomita and K. Inui, 1997. mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Lett., 407: 127-131.
CrossRef  |  
41:   Masuda, S., K. Ibaramoto, A. Takeuchi, H. Saito, Y. Hashimoto and K. Inui, 1999. Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. Mol. Pharmacol., 55: 743-752.
Direct Link  |  
42:   Masuda, S., M. Goto, M. Okuda, Y. Ogura and F. Oike et al., 2005. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc., 37: 1728-1729.
CrossRef  |  
43:   Masuda, S., M. Goto, S. Fukatsu, M. Uesugi and Y. Ogura et al., 2006. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther., 79: 90-102.
CrossRef  |  
44:   Masuda, S., M. Goto, T. Kiuchi, S. Uemoto and T. Kodawara et al., 2003. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Trans., 9: 1108-1113.
CrossRef  |  
45:   Masuda, S., S. Uemoto, M. Goto, Y. Fujimoto, K. Tanaka and K.I. Inui, 2004. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin. Pharmacol. Ther., 75: 352-361.
CrossRef  |  
46:   Masuda, S., S. Uemoto, T. Hashida, Y. Inomata, K. Tanaka and K.I. Inui, 2000. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther., 68: 98-103.
CrossRef  |  
47:   Masuda, S., T. Terada, A. Yonezawa, Y. Tanihara, K. Kishimoto et al., 2006. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 17: 2127-2135.
CrossRef  |  
48:   Mikkaichi, T., T. Suzuki, T. Onogawa, M. Tanemoto and H. Mizutamari et al., 2004. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc. Nat. Acad. Sci. USA., 101: 3569-3574.
Direct Link  |  
49:   Miyagawa‐Hayashino, A., A. Yoshizawa, Y. Uchida, H. Egawa and K. Yurugi et al., 2012. Progressive graft fibrosis and donor‐specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl., 18: 1333-1342.
CrossRef  |  
50:   Motohashi, H., S. Masuda, T. Katsura, H. Saito and S. Sakamoto et al., 2001. Expression of peptide transporter following intestinal transplantation in the rat. J. Surg. Res., 99: 294-300.
CrossRef  |  
51:   Motohashi, H., Y. Sakurai, H. Saito, S. Masuda and Y. Urakami et al., 2002. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13: 866-874.
Direct Link  |  
52:   Nakagawa, S., K. Nishihara, K.I. Inui and S. Masuda, 2012. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur. J. Pharmacol., 696: 143-154.
CrossRef  |  
53:   Nakagawa, S., S. Masuda, K. Nishihara and K.I. Inui, 2010. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem. Pharmacol., 79: 67-76.
CrossRef  |  Direct Link  |  
54:   Nakamura, N., S. Masuda, K. Takahashi, H. Saito, M. Okuda and K.I. Inui, 2004. Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab. Pharmacokinet, 19: 41-47.
CrossRef  |  
55:   Nishihara, K., S. Masuda, H. Shinke, A. Ozawa and T. Ichimura, 2013. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochem. Pharmacol., 85: 570-582.
CrossRef  |  PubMed  |  Direct Link  |  
56:   Nishihara, K., S. Masuda, L. Ji, T. Katsura and K.I. Inui, 2007. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochem. Pharmacol., 73: 1482-1490.
CrossRef  |  Direct Link  |  
57:   Nishihara, K., S. Masuda, S. Nakagawa, A. Yonezawa, T. Ichimura, J.V. Bonventre and K.I. Inui, 2010. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. Am. J. Physiol. Renal. Physiol., 298: F923-F934.
CrossRef  |  Direct Link  |  
58:   Okuda, M., Y. Urakami, S. Masuda, H. Saito and K. Inui, 1997. Characterization of organic ion transporters involved in renal excretion of xenobiotics. Jpn. J. Physiol., 47: S58-S59.
PubMed  |  Direct Link  |  
59:   Omae, T., M. Goto, M. Shimomura, S. Masuda, K. Ito, M. Okuda and K. Inui, 2005. Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. Biochem. Pharmacol., 69: 561-568.
CrossRef  |  
60:   Omote, S., Y. Yano, T. Hashida, S. Masuda, I. Yano, T. Katsura and K.I. Inui, 2009. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol. Pharm. Bull., 32: 99-104.
Direct Link  |  
61:   Omura, T., M. Asari, J. Yamamoto, K. Oka and C. Hoshina,et al., 2013. Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. Biochem. Biophys. Res. Commun., 432: 689-694.
CrossRef  |  PubMed  |  Direct Link  |  
62:   Saito, H., S. Masuda and K.I. Inui, 1996. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem., 271: 20719-20725.
CrossRef  |  
63:   Sakurai, Y., H. Motohashi, H. Ueo, S. Masuda and H. Saito et al., 2004. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm. Res., 21: 61-67.
CrossRef  |  
64:   Sakurai, Y., H. Motohashi, K. Ogasawara, T. Terada and S. Masuda et al., 2005. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm. Res., 22: 2016-2022.
CrossRef  |  
65:   Sato, E., I. Yano, M. Jiko, K. Takahashi and H. Motohashi et al., 2006. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. Biol. Pharm. Bull., 29: 1441-1444.
CrossRef  |  
66:   Sato, E., I. Yano, M. Shimomura, S. Masuda and T. Katsura wt al., 2009. Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. Drug Metab. Pharmacokinet., 24: 175-179.
CrossRef  |  Direct Link  |  
67:   Sato, E., M. Shimomura, S. Masuda, I. Yano and T. Katsura et al., 2006. Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation. Drug Metab. Pharmacokinet, 21: 492-500.
CrossRef  |  
68:   Sato, T., S. Masuda, A. Yonezawa, Y. Tanihara, T. Katsura and K.I. Inui, 2008. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem. Pharmacol., 76: 894-903.
CrossRef  |  Direct Link  |  
69:   Shibata, M., S. Hashi, H. Nakanishi, S. Masuda, T. Katsura and I. Yano, 2012. Detection of 22 antiepileptic drugs by ultra‐performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. Biomed. Chromatogr., 26: 1519-1528.
CrossRef  |  
70:   Shimizu, Y., S. Masuda, K. Nishihara, L. Ji, M. Okuda and K.I. Inui, 2005. Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. Am. J. Physiol. Gastrointest Liver Physiol., 288: 664-670.
CrossRef  |  
71:   Shimomura, M., S. Masuda, H. Saito, S. Sakamoto, S. Uemoto, K. Tanaka and K.I. Inui, 2002. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J. Surg. Res., 103: 215-222.
CrossRef  |  
72:   Shimomura, M., S. Masuda, M. Goto, T. Katsura and T. Kiuchi et al., 2008. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab. Pharmacokinet., 23: 313-317.
Direct Link  |  
73:   Shinke, H., S. Hashi, R. Kinoshita, R. Taniguchi and M. Sugimoto, 2013. Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. Biol. Pharm. Bull., 36: 1221-1225.
PubMed  |  Direct Link  |  
74:   Sugawara-Yokoo, M., Y. Urakami, H. Koyama, K. Fujikura and S. Masuda et al., 2000. Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochem. Cell Biol., 114: 175-180.
CrossRef  |  
75:   Takahashi, K., S. Masuda, N. Nakamura, H. Saito, T. Futami, T. Doi and K.I. Inui, 2001. Upregulation of H(+)-peptide cotransporter PEPT2 in rat remnant kidney. Am. J. Physiol. Renal Physiol., 281: 1109-1116.
CrossRef  |  
76:   Takeuchi, A., S. Masuda, H. Saito, T. Abe and K. Inui, 2001. Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2. J. Pharmacol. Exp. Ther., 299: 261-267.
Direct Link  |  
77:   Takeuchi, A., S. Masuda, H. Saito, T. Doi and K.I. Inui, 2001. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int., 60: 1058-1068.
CrossRef  |  
78:   Takeuchi, A., S. Masuda, H. Saito, Y. Hashimoto and K.I. Inui, 2000. Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1. J. Pharmacol. Exp. Ther., 293: 1034-1039.
Direct Link  |  
79:   Tanihara, Y., S. Masuda, T. Katsura and K.I. Inui, 2009. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem. Pharmacol., 78: 1263-1271.
CrossRef  |  
80:   Tanihara, Y., S. Masuda, T. Sato, T. Katsura, O. Ogawa and K.I. Inui, 2007. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem. Pharmacol., 74: 359-371.
CrossRef  |  Direct Link  |  
81:   Terada, T., S. Masuda, J.I. Asaka, M. Tsuda, T. Katsura and K.I. Inui, 2006. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm. Res., 23: 1696-1701.
CrossRef  |  
82:   Togashi Y., K. Masago, S. Masuda, T. Mizuno, M. Fukudo et al., 2012. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer. Chemother. Pharmacol., 70: 399-405.
CrossRef  |  PubMed  |  Direct Link  |  
83:   Toyama, K., A. Yonezawa, M. Tsuda, S. Masuda and I. Yano et al., 2010. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics, 20: 135-138.
CrossRef  |  PubMed  |  
84:   Toyama, K., A. Yonezawa, S. Masuda, R. Osawa and M. Hosokawa et al., 2012. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin‐induced lactic acidosis. Br. J. Pharmacol., 166: 1183-1191.
CrossRef  |  
85:   Toyohara, T., T. Suzuki, R. Morimoto, Y. Akiyama and T. Souma et al., 2009. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J. Am. Soc. Nephrol., 20: 2546-2555.
CrossRef  |  
86:   Tsuda, M., T. Terada, M. Ueba, T. Sato, S. Masuda, T. Katsura and K.I. Inui, 2009. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther., 329: 185-191.
CrossRef  |  
87:   Uesugi, M., S. Masuda, T. Katsura, F. Oike, Y. Takada and K.I. Inui, 2006. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics, 16: 119-127.
88:   Urakami, Y., M. Okuda, S. Masuda, H. Saito and K. Inui, 1998. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther., 287: 800-805.
Direct Link  |  
89:   Urakami, Y., M. Okuda, S. Masuda, M. Akazawa, H. Saito and K.I. Inui, 2001. Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm. Res., 18: 1528-1534.
CrossRef  |  
90:   Urakami, Y., N. Kimura, M. Okuda, S. Masuda, T. Katsura and K.I. Inui, 2005. Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab. Pharmacokinet, 20: 200-205.
PubMed  |  
91:   Uwai, Y., S. Masuda, M. Goto, H. Motohashi and H. Saito et al., 2004. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J. Human Genet, 49: 40-45.
CrossRef  |  
92:   Yamamoto, S., H. Nakase, M. Matsuura, S. Masuda, K. Inui and T. Chiba, 2011. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J. Clin. Gastroenterol., 45: 526-530.
CrossRef  |  PubMed  |  Direct Link  |  
93:   Yamamoto, S., H. Nakase, M. Matsuura, Y. Honzawa and S. Masuda et al., 2010. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J. Gastroenterol. Hepatol., 25: 886-891.
CrossRef  |  
94:   Yano, I., S. Masuda and K.I. Inui, 2008. Therapeutic Drug Monitoring and Individualized Therapy with Tacrolimus in Recipients of Living-Donor Liver Transplantation. In: Evolution of Living-Donor Liver Transplantation, Tanaka, K., Y. Inomata, S. Uemoto and T. Kiuchi (Eds.). Thomson Reuters, New York, pp: 217-232.
95:   Yano, I., S. Masuda, H. Egawa, M. Sugimoto and M. Fukudo, et al., 2012. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. Eur. J. Clin. Pharmacol., 68: 259-266.
CrossRef  |  PubMed  |  Direct Link  |  
96:   Yao, Y., A. Yonezawa, H. Yoshimatsu, S. Masuda, T. Katsura and K.I. Inui, 2010. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J. Nutr., 140: 1220-1226.
CrossRef  |  
97:   Yokomasu, A., I. Yano, E. Sato, S. Masuda, T. Katsura and K.I. Inui, 2008. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. Drug Metab. Pharmacokinet., 23: 469-475.
Direct Link  |  
98:   Yokomasu, A., I. Yano, E. Sato, S. Masuda, T. Katsura and K.I. Inui, 2009. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. Biopharm. Drug Dispos., 30: 517-523.
CrossRef  |  
99:   Yokoo, S., A. Yonezawa, S. Masuda, A. Fukatsu, T. Katsura and K.I. Inui, 2007. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol., 74: 477-487.
CrossRef  |  Direct Link  |  
100:   Yokoo, S., S. Masuda, A. Yonezawa, T. Terada, T. Katsura and K.I. Inui, 2008. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab. Dispos., 36: 2299-2306.
CrossRef  |  Direct Link  |  
101:   Yokota, A., S. Kimura, S. Masuda, E. Ashihara and J. Kuroda et al., 2007. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 109: 306-314.
CrossRef  |  Direct Link  |  
102:   Yonezawa, A., S. Masuda, K. Nishihara, I. Yano, T. Katsura and K.I. Inui, 2005. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol., 70: 1823-1831.
CrossRef  |  
103:   Yonezawa, A., S. Masuda, S. Yokoo, T. Katsura and K.I. Inui, 2006. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin are substrates for human organic cation transporters (SLC22A1-3 and MATE family). J. Pharmacol. Exp. Ther., 319: 879-886.
PubMed  |  
104:   Yonezawa, A., S. Masuda, T. Katsura and K.I. Inui, 2008. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am. J. Physiol. Cell Physiol., 295: C632-C641.
CrossRef  |  Direct Link  |  
105:   Yoshino, T., H. Nakase, Y. Honzawa, K. Matsumura and S. Yamamoto et al., 2010. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm. Bowel. Dis., 16: 2022-2033.
CrossRef  |  
106:   Yoshitoshi, E.Y., A. Yoshizawa, E. Ogawa, M. Kaneshiro, N. Takada,et al., 2012. The challenge of acute rejection in intestinal transplantation. Pediatr. Surg. Int., 28: 855-859.
CrossRef  |  PubMed  |  Direct Link  |